Durata Therapeutics to Present at the 2013 Credit Suisse Healthcare Conference
November 05, 2013 07:30 ET
|
Durata Therapeutics, Inc.
CHICAGO, Nov. 5, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics (Nasdaq:DRTX) announced today that Paul R. Edick, CEO, will present an overview of the Company at the Credit Suisse Healthcare Conference...
Durata Therapeutics to Announce Third Quarter 2013 Financial Results on November 6, 2013
October 30, 2013 07:30 ET
|
Durata Therapeutics, Inc.
CHICAGO, Oct. 30, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics (Nasdaq:DRTX) has scheduled its quarterly conference call for Wednesday, November 6th at 8:30 a.m. Eastern Time to discuss third quarter...
Durata Therapeutics Presents New Comprehensive Review of the Efficacy and Safety Data of Dalbavancin and New In Vitro Findings at IDWeek 2013(TM)
October 02, 2013 07:30 ET
|
Durata Therapeutics, Inc.
SAN FRANCISCO, Oct. 2, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc. (Nasdaq:DRTX) today announced a comprehensive review of the efficacy, safety and microbiology data of the company's lead...
Durata Therapeutics Announces NDA Submission for Dalbavancin for the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
September 26, 2013 14:48 ET
|
Durata Therapeutics, Inc.
CHICAGO, Sept. 26, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc. (Nasdaq:DRTX), an emerging specialty pharmaceutical company, today announced that it has submitted a New Drug Application (NDA) to...
Dalbavancin Study Results to be Presented at IDWeek 2013
September 25, 2013 07:30 ET
|
Durata Therapeutics, Inc.
CHICAGO, Sept. 25, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc. (Nasdaq:DRTX) today announced that data from the company's lead product candidate, dalbavancin, will be presented in five posters...
Durata Therapeutics Presents New Pivotal Phase 3 Clinical Results and New In Vitro Data on Dalbavancin at ICAAC
September 10, 2013 15:12 ET
|
Durata Therapeutics, Inc.
DENVER, Sept. 10, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc. (Nasdaq:DRTX) today presented clinical trial results from its two Phase 3 DISCOVER ("Dalbavancin for Infections of the Skin...
Dalbavancin Study Results to be Presented in Three Posters at the 53rd Annual ICAAC Meeting
September 03, 2013 15:03 ET
|
Durata Therapeutics, Inc.
CHICAGO, Sept. 3, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc. (Nasdaq:DRTX) today announced that data from two Phase 3 clinical trials of the company's lead product candidate, dalbavancin, will...
Durata Therapeutics, Inc. Reports Second Quarter 2013 Financial Results
August 07, 2013 07:30 ET
|
Durata Therapeutics, Inc.
CHICAGO, Aug. 7, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc. (Nasdaq:DRTX) today announced financial results for the quarter ended June 30, 2013.
Q2 2013 Highlights and Recent...
Durata Therapeutics to Present at the 2013 Wedbush Securities Life Sciences Management Access Conference
August 06, 2013 07:30 ET
|
Durata Therapeutics, Inc.
CHICAGO, Aug. 6, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics (Nasdaq:DRTX) announced today that Paul R. Edick, CEO, will present an overview of the Company at the Wedbush Securities Life Sciences...
Durata Therapeutics to Announce Second Quarter 2013 Financial Results on August 7, 2013
July 31, 2013 07:30 ET
|
Durata Therapeutics, Inc.
CHICAGO, July 31, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics (Nasdaq:DRTX) has scheduled its quarterly conference call for Wednesday, August 7th at 8:30 a.m. Eastern Time to discuss second quarter...